medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2014, Number 2

<< Back Next >>

Rev Mex Patol Clin Med Lab 2014; 61 (2)

Recovery of the left ventricular fraction ejection in patients with acute myocardial infarction perioperation treated with colonial granulocytes stimulating factor

Hussein AA, Valdés RY, Carnot UJ, de la Campa JD, Marcel EA, Colao-Jiménez Y, Chaos-González N, Amador-Acuña MG, Romero-González R, Abi-Rezk MN

Language: Spanish
References: 25
Page: 118-124
PDF size: 296.27 Kb.


ABSTRACT

Perioperative myocardial infarction (PMI) is a relatively frequent complication after cardiac surgical e important cause of morbidity and mortality. In this study, ten patients were included to surgical myocardial revascularization (SMR) with PMI, entered in the Service of Cardiovascular Surgery of the Hospital «Hermanos Ameijeiras» of September of the 2010 to December of the 2011. Our objective is to contribute the regeneration of the myocardial infarction, through the mobilization of hematopoietic stem cells (HSCs) of bone marrow (BMC) to outlying circulates by means of the administration of the granulocyte colony-stimulating factor (G-CSF), to the dose of 5 µg/kg each 12 h during five days, to the week and the month with PMI. This each 48 h was evaluated, after administering the G-CSF, for automated count of leukocytes and the identification and count of the HSC CD34+, by means of the parametric analysis of the flow cytometry (FC), using those conjugated of anti-CD34+ monoclonal antibodies (anti-CD34+(REP) mAb) and anti-CD45+(FITC) mAb to evaluate the recovery of the heart function the recovery of the fraction of ejection ventricular left it was used (FEVL). In the results was a significant increment of the population of mononuclear cells (MNC) CD34+ (p ‹ 0,01) in blood that, he/she was related with the significant reduction of the time of recovery of the FEVI (53.60 ± 7.87 versus 44.60 ±11.75; p = 0.0019) to 3 months because, the patients with IAMP, to those that were not administered the FEC-G, delayed among 6-12 months to recover the FEVL, that which indicates that the FEC-G may also offer a strategy for cardiac regeneration.


REFERENCES

  1. Fernández-García RA, Silveira-Álvarez A, Milán-González E, Pérez-Navarro A, Paredes-Cordero AM, Cabrera-Rego JO et al. Factores asociados a infarto agudo de miocardio perioperatorio en cirugía cardiaca. Rev Fed Arg Cardiol. 2012; 41 (2): 103-108.

  2. Abi-Rezk MN, Hernández NR, Carballo HN, Villar IA, Guevara GL, Chaos GN, Chil DR, Rodríguez RK. Resultados de la revascularización coronaria en el cardiocentro del Hospital «Hermanos Ameijeiras», en un período de 20 años Revista Cubana de Cirugía 2011: 50 (1): 54-72.

  3. Anversa P, Kajstura J, Leri A, Bolli R Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation. 2006; 13: 1451-1463.

  4. Torella D, Ellison GM, Nadal-Ginard B and Indolfi C. Cardiac stem and progenitor cell biology for regenerative medicine. Trends Cardiovasc Med. 2005; 15: 229-236.

  5. Yousef M, Schannwell CM, Kostering M, et al. The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol. 2009; 53: 2262-2269.

  6. Perin EC, Silva GV, Henry TD et al. A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J. 2011; 161: 1078-1087.

  7. Khan NE, De Souza A, Mister R et al. A randomized comparison of off-pump and on- pump multivessel coronary-artery bypass surgery. N Engl J Med. 2008; 350: 21-28.

  8. Hennig RJ. Stem cells in cardiac repair- Recent development and future drection. Interventional Cardiology. 2012; 7 (1): 10-13.

  9. Maroto L, Di Etefano S, Arnold R, Revilla A, Arroyo A, Valenzuela H, Laguna G, Pareja P et al. Terapia celular durante la revascularización quirúrgica en el infarto agudo del miocardio. Rev Cir Cardiovasc. 2012; 19 (2): 176.

  10. Daniel A, Jones DA, Choudry F, Mathu A. Almanac 2012. Terapia celular en la enfermedad cardiovascular. Rev Urug Cardiol. 2013; 28: 247-256.

  11. Seth S, Bhargava B, Narang R et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial a long-termfollow-up study. J AmColl Cardiol. 2010; 55: 1643-1644.

  12. Traverse JH, Henry TD, Ellis SG et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the late time randomized trial. JAMA. 2011; 306: 2110-2119.

  13. Oh Y, Wei H, Ma D et al. Clinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine. Heart. 2012; 98: 443-449.

  14. Martin-Rendon E, Brunskill SJ, Hyde CJ et al. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J. 2008; 29: 1807-1818

  15. Beitnes JO, Hopp E, Lunde K et al. Long-term results after intracoronary injection of autologous mono nuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised, controlled study. Heart. 2009; 95: 1983-1989.

  16. Losordo DW, Henry TD, Davidson C et al. Intramyocardial, autologous CD34+cell therapy for refractory angina. Circ Res. 2011; 109: 428-436.

  17. Barriga F. Células madre: Usos presente y futuro. Rev. Med Cin. CONDES-2008; 19 (3): 290-293.

  18. Dorticós BE, Hernández RP. Medicina regenerativa: Células madre en enfermedades del corazón. Rev Cub Hematol Inmunol Hemoter. 2006; 22 (1): 1.

  19. Análisis de Situación | Terapia Celular y Medicina Regenerativa. En: Estrategia y Plan de Actuación 2010/2015. Iniciativa Andaluza en Terapias Avanzadas.

  20. Domínguez H, Hurlé, A. Conferencia. Terapias de Avanzada y Desarrollo de Medicina de Salamanca. Salamanca; 2012. pp. 7-71

  21. Hernández RP. Medicina regenerativa II. Aplicaciones, realidad y perspectivas de la terapia celular. Rev Cub Hematol Inmunol Hemoter. 2006; 22 (3): 1-20.

  22. Hernández-Ramírez P, Alfonso-Simón A, Aparicio Suarez JL et al. Experiencia cubana con el uso terapéutico de células madre adultas. Rev Cub Hematol Inmunol Hemoter. 2011; 27 (1): 139-163.

  23. Asociacion Médica Mundial. Declaración de Helsinki. Principios éticos para la investigación médica en seres humanos. Ferney-Voltaire, Franc: AMM; 2004 Disponible en http: //www.wma.net/s/policy/b3.htm

  24. González AI, Forrellat M, González T et al. Obtención y procesamiento de progenitores hematopoyéticos de sangre periférica para terapia celular en enfermedades angiológicas. Rev Cub Hematol Inmunol Hemoter. 2011; 27 (3): 356-364. http: //scielo.sld.cu/scielo.php?script=sci.

  25. Borowitz MJ, Guenther KL, Shults KE, Stelzer GT. Immunophenotyping of acute leukemia by flow cytometric analysis: use of CD45 and right-angle light scatter to gate on leukemic blasts in three color analysis. Am J Clin Pathol. 1993; 100: 534-540.




2020     |     www.medigraphic.com